Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

and heart rate for Empatic are similar to or more favorable than the placebo-subtracted changes observed with Contrave, and there are no signals of cardiovascular concern in the Empatic development program, reassuring results of a cardiovascular outcomes trial with Contrave will be sufficient. In addition, while the FDA reiterated the belief that the teratogenicity potential for zonisamide is very concerning, the FDA will allow Phase 3 studies of Empatic to include women of childbearing potential who have a Body Mass Index that meets the FDA definition of overweight (>27kg/m2) in the presence of at least one weight-related comorbidity. Orexigen owns worldwide rights to Empatic. Prior to initiating Phase 3 studies of Empatic, the Company plans to seek a collaboration partner to help fund further clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the second quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 35366685. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  Today the U.S. ... Novartis, Bexsero® for the prevention of serogroup B ... Bexsero and Pfizer,s vaccine Trumenba®, which received FDA approval ... prevent this devastating disease. "I have ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Jan. 23, 2015 More than a third of reproductive-aged ... those with private insurance, filled a prescription for an opioid ... in this week,s Morbidity and Mortality Weekly Report (MMWR). ... to treat moderate to severe pain.  They are also found ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... , MORRISVILLE, N.C., Nov. 16 nContact Surgical, Inc. ... non-invasive treatment for heart conditions, today announced the initiation ... and efficacy of its Numeris® - AF ... open-chest concomitant procedure for the treatment of longstanding persistent ...
... , WALTHAM, Mass., Nov. ... research and advisory firms for pharmaceutical and healthcare issues, ... the methicillin-resistant Staphylococcus aureus (MRSA) drug market ... three emerging agents from Theravance/Astellas, Johnson & Johnson/Basilea and ...
Cached Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures 2Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 2Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... four private companies took over the reins of the contract, ... huge problems for patients for whom oxygen supply can mean ... about 60,000 people are in need of oxygen at home ... of Oxygen have taken a beating. A woman reportedly died ...
... survey reported an increased level of mercury in some ... // There were state wide tests conducted in the ... women of child-bearing age should eat only one meal ... Environmental Protection Agency guidelines the mercury contamination in the ...
... pediatrics at the Medical College of Wisconsin said that adult ... ,Both have different levels of chemicals (enzymes) in their ... in concentration with age. ,Hence this study suggests ... the young. ,This plays a vital role because ...
... marked as the National Children's Dental Health Month and ... widespread use of fluorides and school water // fluoridation ... However, it must be pointed out that the problem ... ,Baby Bottle Tooth Decay affects more infants ...
... International Journal of Cancer on February 17, 2006 tries to ... the level of physical activity in women. // The prospective ... link. ,Experts felt that since exercise is known ... the gastrointestinal transit time, it might also play a constructive ...
... solid organ. In UK there is an increase in demand as ... who do not receive transplants.// ,Hence it was decided ... of organs by as much as 20%. This was reported in ... supply of human organs for transplantation. , ,In general ...
Cached Medicine News:Health News:Rise in Mercury Levels in Supermarket Fish 2Health News:Women, Exercise and Colon Cancer 2
Developed specifically for the 5000/5500 ultrasound consoles....
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
This unique tiny transducer can be very helpful in tight situations like during a carotid endardarectomy procedure....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
Medicine Products: